BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292]
URL: https://www.wjgnet.com/1007-9327/full/v13/i8/1292.htm
Number Citing Articles
1
Current awareness: Pharmacoepidemiology and drug safetyPharmacoepidemiology and Drug Safety 2007; 16(11) doi: 10.1002/pds.1377
2
Xian-Ling Wang, Yi-Ming Mu, Zhao-Hui Lu, Ju-Ming Lu, Jing-Tao Dou, Chang-Yu Pan. Type 1 Diabetes Caused by Interferon α-2α in Polycythemia Vera TherapyDiabetes Care 2010; 33(11) doi: 10.2337/dc10-1266
3
Current World LiteratureCurrent Opinion in Endocrinology, Diabetes & Obesity 2008; 15(2) doi: 10.1097/MED.0b013e3282fba8b4
4
Current World LiteratureCurrent Opinion in Endocrinology, Diabetes & Obesity 2007; 14(5) doi: 10.1097/MED.0b013e3282f0ca40
5
Simona Cristina (Nicolescu) Marinescu, Miruna-Maria Apetroaei, Marina Ionela (Ilie) Nedea, Andreea Letiția Arsene, Bruno Ștefan Velescu, Sorina Hîncu, Emilia Stancu, Anca Lucia Pop, Doina Drăgănescu, Denisa Ioana Udeanu. Dietary Influence on Drug Efficacy: A Comprehensive Review of Ketogenic Diet–Pharmacotherapy InteractionsNutrients 2024; 16(8) doi: 10.3390/nu16081213
6
Paola Tarabini-Castellani, Leire Apraiz, Joseba Portu, José Manuel Agud. Diabetes mellitus en relación con tratamiento con interferónEnfermedades Infecciosas y Microbiología Clínica 2008; 26(2) doi: 10.1157/13115550
7
Marna G. Bouwhuis, Stefan Suciu, Alessandro Testori, Wim H. Kruit, François Salès, Poulam Patel, Cornelis J. Punt, Mario Santinami, Alain Spatz, Timo L.M. ten Hagen, Alexander M.M. Eggermont. Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodies—EORTC 18991Journal of Clinical Oncology 2010; 28(14) doi: 10.1200/JCO.2009.24.6264
8
Yuan-Yuan Lv, Bing-Yin Shi, Hui Guo. Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis BWorld Journal of Gastroenterology 2008; 14(29): 4713-4715 doi: 10.3748/wjg.14.4713
9
Corrado Betterle, Fabio Presotto. HCV Infection and Cryoglobulinemia2012;  doi: 10.1007/978-88-470-1705-4_5
10
Hiroaki Yagyu, Kenta Okada, Shin Sato, Yumiko Yamashita, Nobukazu Okada, Jun-ichi Osuga, Shoichiro Nagasaka, Kentaro Sugano, Shun Ishibashi. Pegylated interferon-α2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitusDiabetes Research and Clinical Practice 2012; 95(3) doi: 10.1016/j.diabres.2011.11.016
11
Maria Xenou, Ioannis Zoupas, Dimitrios Lygnos, Evangelos Fousteris. Diabetic ketoacidosis as first presentation of latent autoimmune diabetes in adults in a patient with hashitoxicosis as first presentation of Hashimoto’s thyroiditis: a case reportJournal of Medical Case Reports 2022; 16(1) doi: 10.1186/s13256-022-03523-3
12
Yun Nah Lee, Soung Won Jeong, Jae Hee Lim, Yang Seon Ryu, Seong Ran Jeon, Sang Kyun Kim, Jae Young Jang, Young Seok Kim, Boo Sung Kim, Mi Oh Roh. Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis CThe Korean Journal of Hepatology 2010; 16(2) doi: 10.3350/kjhep.2010.16.2.187
13
Reiko Oka, Naoki Hiroi, Rika Shigemitsu, Mariko Sue, Yasuo Oshima, Mayumi Yoshida-Hiroi. Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature ReviewClinical Medicine Insights: Endocrinology and Diabetes 2011; 4 doi: 10.4137/CMED.S7815
14
Daniel Lewis, Corinna van den Heuvel, Michaela Kenneally, Roger W Byard. Methamphetamine use and the risk of diabetic ketoacidosisMedicine, Science and the Law 2022; 62(1) doi: 10.1177/00258024211020936
15
Masayuki Hayashi, Yuko Kataoka, Kazushige Tachikawa, Hiroki Koguchi, Hiroshi Tanaka. Dual onset of type 1 diabetes mellitus and Graves’ disease during treatment with pegylated interferon α-2b and ribavirin for chronic hepatitis CDiabetes Research and Clinical Practice 2009; 86(2) doi: 10.1016/j.diabres.2009.08.009
16
Linghuan Wang, Kang Chen, Meirong Wang, Zhaohui Lv, Weijun Gu, Xianling Wang, Qi Ni, Yiming Mu. Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A ReviewHormone and Metabolic Research 2022; 54(03) doi: 10.1055/a-1749-5716
17
Linghuan Wang, Binqi Li, He Zhao, Peixin Wu, Qingzhen Wu, Kang Chen, Yiming Mu. A systematic review and meta-analysis of endocrine-related adverse events associated with interferonFrontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.949003
18
Taiba Zornitzki, Stephen Malnick, Lyudmila Lysyy, Hilla Knobler. Interferon therapy in hepatitis C leading to chronic type 1 diabetesWorld Journal of Gastroenterology 2015; 21(1): 233-239 doi: 10.3748/wjg.v21.i1.233